171 related articles for article (PubMed ID: 29796761)
1. Treatment of Intracerebral Lesions with Abatacept in a CTLA4-Haploinsufficient Patient.
van Leeuwen EM; Cuadrado E; Gerrits AM; Witteveen E; de Bree GJ
J Clin Immunol; 2018 May; 38(4):464-467. PubMed ID: 29796761
[No Abstract] [Full Text] [Related]
2. Abatacept for treatment-refractory pediatric CTLA4-haploinsufficiency.
Lanz AL; Riester M; Peters P; Schwerd T; Lurz E; Hajji MS; Rohlfs M; Ley-Zaporozhan J; Walz C; Kotlarz D; Klein C; Albert MH; Hauck F
Clin Immunol; 2021 Aug; 229():108779. PubMed ID: 34116213
[TBL] [Abstract][Full Text] [Related]
3. Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4.
Lee S; Moon JS; Lee CR; Kim HE; Baek SM; Hwang S; Kang GH; Seo JK; Shin CH; Kang HJ; Ko JS; Park SG; Choi M
J Allergy Clin Immunol; 2016 Jan; 137(1):327-330. PubMed ID: 26478010
[No Abstract] [Full Text] [Related]
4. Assessment of CTLA-4 Deficiency-Related Autoimmune Choroidopathy Response to Abatacept.
Shields CL; Say EA; Mashayekhi A; Garg SJ; Dunn JP; Shields JA
JAMA Ophthalmol; 2016 Jul; 134(7):844-6. PubMed ID: 27258812
[No Abstract] [Full Text] [Related]
5. Abatacept is useful in autoimmune cytopenia with immunopathologic manifestations caused by CTLA-4 defects.
Dhunputh C; Ducassou S; Fernandes H; Picard C; Rieux-Laucat F; Viallard JF; Lazaro E; Hermine O; Jouvray M; Machelard I; Lambilliotte A; Malphettes M; Moshous D; Neven B; Gauthier A; Garnier N; Leblanc T; Landman-Parker J; Leverger G; Aladjidi N
Blood; 2022 Jan; 139(2):300-304. PubMed ID: 34714911
[No Abstract] [Full Text] [Related]
6. Preponderance of
Siggs OM; Russell A; Singh-Grewal D; Wong M; Chan P; Craig ME; O'Loughlin T; Stormon M; Goodnow CC
Front Immunol; 2019; 10():1544. PubMed ID: 31396201
[TBL] [Abstract][Full Text] [Related]
7. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy.
Lo B; Zhang K; Lu W; Zheng L; Zhang Q; Kanellopoulou C; Zhang Y; Liu Z; Fritz JM; Marsh R; Husami A; Kissell D; Nortman S; Chaturvedi V; Haines H; Young LR; Mo J; Filipovich AH; Bleesing JJ; Mustillo P; Stephens M; Rueda CM; Chougnet CA; Hoebe K; McElwee J; Hughes JD; Karakoc-Aydiner E; Matthews HF; Price S; Su HC; Rao VK; Lenardo MJ; Jordan MB
Science; 2015 Jul; 349(6246):436-40. PubMed ID: 26206937
[TBL] [Abstract][Full Text] [Related]
8. Immune dysregulation syndrome with de novo CTLA4 germline mutation responsive to abatacept therapy.
Ureshino H; Koarada S; Kamachi K; Yoshimura M; Yokoo M; Kubota Y; Ando T; Ichinohe T; Morio T; Kimura S
Int J Hematol; 2020 Jun; 111(6):897-902. PubMed ID: 31993940
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic modalities and clinical outcomes in a large cohort with LRBA deficiency and CTLA4 insufficiency.
Taghizade N; Babayeva R; Kara A; Karakus IS; Catak MC; Bulutoglu A; Haskologlu ZS; Akay Haci I; Tunakan Dalgic C; Karabiber E; Bilgic Eltan S; Yorgun Altunbas M; Sefer AP; Sezer A; Kokcu Karadag SI; Arik E; Karali Z; Ozhan Kont A; Tuzer C; Karaman S; Mersin SS; Kasap N; Celik E; Kocacik Uygun DF; Aydemir S; Kiykim A; Aydogmus C; Ozek Yucel E; Celmeli F; Karatay E; Bozkurtlar E; Demir S; Metin A; Karaca NE; Kutukculer N; Aksu G; Guner SN; Keles S; Reisli I; Kendir Demirkol Y; Arikoglu T; Gulez N; Genel F; Kilic SS; Aytekin C; Keskin O; Yildiran A; Ozcan D; Altintas DU; Ardeniz FO; Dogu EF; Ikinciogullari KA; Karakoc-Aydiner E; Ozen A; Baris S
J Allergy Clin Immunol; 2023 Dec; 152(6):1634-1645. PubMed ID: 37595759
[TBL] [Abstract][Full Text] [Related]
10. CTLA4-Ig: a novel immunosuppressive agent.
Najafian N; Sayegh MH
Expert Opin Investig Drugs; 2000 Sep; 9(9):2147-57. PubMed ID: 11060799
[TBL] [Abstract][Full Text] [Related]
11. Gastric cancer, inflammatory bowel disease and polyautoimmunity in a 17-year-old boy: CTLA-4 deficiency successfully treated with Abatacept.
Angelino G; Cifaldi C; Zangari P; Di Cesare S; Di Matteo G; Chiriaco M; Francalanci P; Faraci S; Rea F; Romeo EF; Amodio D; Ursu GM; Bertocchini A; Accinni A; Crocoli A; Inserra A; Cozza R; Romano C; Licciardello M; Rinelli M; Dall'Oglio L; Cancrini C; De Angelis P; Finocchi A
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e1051-e1056. PubMed ID: 34034269
[TBL] [Abstract][Full Text] [Related]
12. A Patient with CTLA-4 Haploinsufficiency with Multiple Autoimmune Presentations: A Case Report.
Zaremehrjardi F; Baniadam L; Seif F; Arshi S; Bemanian MH; Shokri S; Rezaeifar A; Fallahpour M; Nabavi M
Iran J Immunol; 2020 Sep; 17(3):244-249. PubMed ID: 32996901
[TBL] [Abstract][Full Text] [Related]
13. Abatacept and granulocyte-colony stimulating factor in a patient with rheumatoid arthritis and neutropenia.
Priora M; Parisi S; Scarati M; Borrelli R; Peroni CL; Fusaro E
Immunotherapy; 2017 Oct; 9(13):1055-1059. PubMed ID: 28967792
[TBL] [Abstract][Full Text] [Related]
14. Rescue of Cytokine Storm Due to HLH by Hemoadsorption in a CTLA4-Deficient Patient.
Greil C; Roether F; La Rosée P; Grimbacher B; Duerschmied D; Warnatz K
J Clin Immunol; 2017 Apr; 37(3):273-276. PubMed ID: 28265964
[No Abstract] [Full Text] [Related]
15. Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease.
Danion F; Rosine N; Belkhir R; Gottenberg JE; Hachulla E; Chatelus E; Pugnet G; Pers YM; Mariette X; Sibilia J; Seror R;
Lupus; 2016 Nov; 25(13):1440-1447. PubMed ID: 27013663
[TBL] [Abstract][Full Text] [Related]
16. Murine LRBA deficiency causes CTLA-4 deficiency in Tregs without progression to immune dysregulation.
Burnett DL; Parish IA; Masle-Farquhar E; Brink R; Goodnow CC
Immunol Cell Biol; 2017 Oct; 95(9):775-788. PubMed ID: 28611475
[TBL] [Abstract][Full Text] [Related]
17. Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency.
Bakacs T; Mehrishi JN
Immunobiology; 2015 May; 220(5):624-5. PubMed ID: 25638260
[TBL] [Abstract][Full Text] [Related]
18. Underlying CTLA4 Deficiency in a Patient With Juvenile Idiopathic Arthritis and Autoimmune Lymphoproliferative Syndrome Features Successfully Treated With Abatacept-A Case Report.
Mazzoni M; Dell'Orso G; Grossi A; Ceccherini I; Viola S; Terranova P; Micalizzi C; Guardo D; Massaccesi E; Palmisani E; Calvillo M; Fioredda F; Malattia C; Dufour C; Ravelli A; Miano M
J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1168-e1172. PubMed ID: 33625086
[TBL] [Abstract][Full Text] [Related]
19. Two neurologic facets of CTLA4-related haploinsufficiency.
Ayrignac X; Goulabchand R; Jeziorski E; Rullier P; Carra-Dallière C; Lozano C; Portales P; Vincent T; Viallard JF; Menjot de Champfleur N; Rieux-Laucat F; Besnard C; Koenig M; Guissart C; Labauge P; Guilpain P
Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32499327
[TBL] [Abstract][Full Text] [Related]
20. Polymorphic alleles in exon 1 of the CTLA4 gene do not predict the response to abatacept.
Talotta R; Bagnato GL; Atzeni F; Ditto MC; Bitto A; Squadrito F; Lo Gullo A; Sarzi-Puttini P; Bagnato GF
Clin Exp Rheumatol; 2013; 31(5):813. PubMed ID: 23739065
[No Abstract] [Full Text] [Related]
[Next] [New Search]
